UNSPSC 51202805: Tacrolimus anhydrous

This classification denotes a mtor inhibitor and immunosuppressant with the molecular formula C44H69NO12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y5L2157C4J, chemically known as tacrolimus, anhydrous, but more generally known as tacrolimus anhydrous, which bears US NIH Compound Identifier 6436007. European Medicines Agency schedules tacrolimus anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10797MIG.

Most nations, for tariff purposes, schedule tacrolimus anhydrous under HS 29349990. Tacrolimus anhydrous bears US NLM identifiers UMLS ID C0771204 and NCI Concept Code C76066. SMILES: C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC.

UNSPSC 51202805 Tacrolimus anhydrous is a Commodity code for a specific immunosuppressant pharmaceutical product. Recent state and local procurement activity under this code shows minimal relevant activity; the two most recent opportunities tagged to the code involve Doxycycline Hyclate, Ciprofloxacin Hydrochloride, Naloxone, and drug deactivation systems—none of which are tacrolimus. The mismatch suggests either tagging error in the source data or that tacrolimus procurement by state and local entities falls below the visibility threshold of current opportunity records. When state and local governments do procure tacrolimus, they typically source it through pharmaceutical warehousing contracts, piggyback purchasing arrangements with established consortiums such as MMCAP Infuse, or direct purchase orders from hospital systems and health departments managing transplant and immunosuppression programs.

The Illinois Department of Public Health's piggyback pharmaceutical warehouse contract awarded to Chartwell Rx LLC in August 2026 represents the contracting structure through which tacrolimus would be acquired—multi-product pharmaceutical supply arrangements via established group purchasing organizations—but does not confirm active tacrolimus procurement under this code at present. Geographic activity appears scattered across state health departments and county-level public health agencies when pharmaceutical procurement does occur, but no clear concentration or standout repeat buyer emerges from the recent opportunities block. Until tacrolimus-specific solicitations appear in state and local procurement records, this code presents limited immediate opportunity signals for vendors targeting institutional pharmaceutical supply contracts.